The experience of uterine fibroids treatment with selective progesterone-receptor modulator

Adamyan L.V.

Department of Reproductive Medicine and Surgery, Faculty of Postgraduate Professional Education, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

SPIN RSCI: 9836-2713
Scopus AuthorID: 7006372422
ResearcherID: Q-1722-2018
ORCID: 0000-0002-3253-4512

Sonova M.M.

Kafedra reproduktivnoĭ meditsiny i khirurgii fakul'teta poslediplomnogo obrazovaniia Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Shamugia N.M.

The experience of uterine fibroids treatment with selective progesterone-receptor modulator

Authors:

Adamyan L.V., Sonova M.M., Shamugia N.M.

More about the authors

Journal: Russian Journal of Human Reproduction. 2014;(4): 34‑38

Downloaded: 92

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Adamyan LV, Sonova MM, Shamugia NM. The experience of uterine fibroids treatment with selective progesterone-receptor modulator. Russian Journal of Human Reproduction. 2014;(4):34‑38. (In Russ.)

Close metadata

Recommended articles:

Benign breast diseases in the focus of proliferative pathology of the reproductive system. Russian Journal of Human Reproduction. 2024;(3):33-42

A clinical case of parasitic fibroids on the mesentery of the sigmoid colon. Russian Journal of Human Reproduction. 2024;(3):105-110

Tolerability of multiphasic and monophasic combined hormonal contraceptives patients with uterine fibroids. Russian Journal of Human Reproduction. 2024;(4):78-89

Heterogeneity of the molecular phenotype with uterine fibroids. Message I. Russian Journal of Human Reproduction. 2024;(4):121-130

Heterogeneity of the molecular phenotype with uterine fibroids. Message II. Russian Journal of Human Reproduction. 2024;(5):15-24

Gonadotropin-releasing hormone agonists as a chance for motherhood in the future. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):30-36

Controversial issues of adjuvant therapy after myomectomy. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):101-107

Structural and biochemical features of menstrual discharge in patients with uterine fibroids. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):85-90

The experience of Ulipristal acetate as selective progesterone-receptor modulator which inhibits the proliferation and induces apoptosis of leiomyoma cells in vitro is presented. It modulates the expression of vascular endothelial growth factors and hormone receptors and modulates the extracellular matrix breakdown in leiomyoma cells but not in myometrial cells. Uterine bleeding was rapidly controlled by ulipristal acetate. About half of patients received of ulipristal acetate 5 mg/day became amenorrhoeic within the first 10 days of treatment. Furthermore, uterine bleeding was controlled significantly more rapidly with Ulipristal acetate compared with leuprolide acetate.

Keywords:

leiomyoma

Ulipristal acetate

agonists GnRH